	US 12,350,302 B2
	Dosing regime and formulations for type B adenoviruses
John Beadle, Abingdon (GB); Kerry Fisher, Abingdon (GB); and Christine Wilkinson Blanc, Abingdon (GB)
Assigned to Akamis Bio Limited, Abingdon (GB)
Filed by AKAMIS BIO LIMITED, Abingdon (GB)
Filed on Sep. 23, 2021, as Appl. No. 17/448,549.
Application 17/448,549 is a continuation of application No. 14/896,294, granted, now 11,173,186, previously published as PCT/EP2014/062284, filed on Jun. 12, 2014.
Claims priority of application No. 1310698 (GB), filed on Jun. 14, 2013; application No. 1405140 (GB), filed on Mar. 22, 2014; and application No. 1406509 (GB), filed on Apr. 10, 2014.
Prior Publication US 2022/0054563 A1, Feb. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/761 (2015.01); A61K 9/00 (2006.01); A61K 31/337 (2006.01); A61K 33/243 (2019.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01); A61K 45/06 (2006.01); C12N 7/00 (2006.01)

CPC A61K 35/761 (2013.01) [A61K 9/0019 (2013.01); A61K 31/337 (2013.01); A61K 33/243 (2019.01); A61K 38/19 (2013.01); A61K 38/2013 (2013.01); A61K 38/212 (2013.01); A61K 38/217 (2013.01); A61K 45/06 (2013.01); C12N 7/00 (2013.01); C12N 2710/10021 (2013.01); C12N 2710/10032 (2013.01); C12N 2710/10071 (2013.01); C12N 2710/10332 (2013.01)]

20 Claims

1. A method of treating cancer in a human patient, comprising intravenously administering to the patient multiple doses of a formulation of a replication competent oncolytic adenovirus of subgroup B in a single treatment cycle,

wherein a total dose given in each administration is in the range of 1×10¹²to 1×10¹³viral particles, and

wherein the rate of viral particle delivery for each administered dose of adenoviruses is in the range of 2×10¹⁰to 6×10¹¹particles per minute.